Follow The Filings

TRVI Trevi Therapeutics Inc.

Health Care, filed as TREVI THERAPEUTICS INC (COM), Equity As of 2026 Q2 among managers we track Quote on Google Finance, opens in a new tab

Sold by 2 managers in 2026 Q2

  • 3 Owners
  • Max 0.5%
  • $35M
  • 2 reduce

In 2026 Q2 James Silverman and Andreas Halvorsen trimmed Trevi Therapeutics.

Who owns this now

Largest portfolio weights among holders, up to 0.5% (James Silverman, Opaleye Management). Not free-float ownership.

  1. James Silverman Reduce 0.52%
  2. Andreas Halvorsen Reduce 0.08%
  3. David Witzke 0.02%

Who owns TRVI

Sorted by value, long equity only, as of 2026 Q2.

History
Andreas Halvorsen, Viking Global Investors 0.08%, was 0.10% Reduce −51.7% 1,544,644 $29M History
James Silverman, Opaleye Management 0.52%, was 0.54% Reduce −10.2% 310,000 $5.8M History
David Witzke, Avidity Partners Management 0.02% Hold 6,660 $124K History

3 current, options excluded

Weight bar: held both quarters added sold at this quarter’s reported price

Insider trades

Open-market buys and sales by TRVI's executives, directors and 10% owners in the last 12 months, from their Form 4s

All TRVI insider trades
  • None no insider bought on the open market
  • None no sales outside a trading plan
  • $596K sold by 1 insider under 10b5-1 plans
  1. Michael Thomas Heffernan Director
    Planned sale
    $596K 39,473 shares at $15.09 86% of stake
    Traded Sep 15 Filed Sep 17
    ↗

Also filed in the last 12 months, not counted as buying or selling: 3 option exercises.

SEC filings

Recent issuer filings from EDGAR, 25 shown.

Filed Form Detail Links
SCHEDULE 13G/A — Filing Doc
8-K 2.02,9.01 Filing Doc
10-Q Filing Doc
8-K 5.03,5.07,9.01 Filing Doc
SCHEDULE 13D/A — Filing Doc
SCHEDULE 13G/A — Filing Doc
8-K 2.02,9.01 Filing Doc
10-Q Filing Doc
DEF 14A Filing Doc
DEFA14A Filing Doc
8-K 1.01,2.02,8.01,9.01 Filing Doc
424B5 Filing Doc
424B5 Filing Doc
SCHEDULE 13G/A — Filing Doc
8-K 2.02,9.01 Filing Doc
10-K Filing Doc
8-K 8.01 Filing Doc
SCHEDULE 13D/A — Filing Doc
SCHEDULE 13G/A — Filing Doc
SCHEDULE 13G — Filing Doc
SCHEDULE 13G — Filing Doc
8-K 5.02 Filing Doc
SCHEDULE 13G/A — Filing Doc
SCHEDULE 13G/A — Filing Doc
8-K 2.02,9.01 Filing Doc

Source: SEC EDGAR submissions, updated 6 days ago. All on EDGAR

Financials

US-GAAP annual figures by fiscal year, as tagged in Form 10-K. Each value links to its SEC filing.

Income statement

Metric FY2023 FY2024 FY2025
Net income -$29.06M -$47.91M -$42.76M

Balance sheet

Metric FY2023 FY2024 FY2025
Total current assets $87.55M $109.43M $191.66M
Total non-current assets * $1.86M $1.47M $1.78M
Total assets $89.4M $110.9M $193.44M
Total current liabilities $5.82M $10.51M $9.75M
Total non-current liabilities * $1.03M $0.747M $0.446M
Total equity $82.55M $99.64M $183.24M

Cash flow

Metric FY2023 FY2024 FY2025
Cash from operations -$31.71M -$38.26M -$42.09M
Cash from investing $59.43M -$21.53M -$94.11M
Cash from financing -$7.91M $61.48M $121.01M
Net change in cash $19.81M $1.7M -$15.18M

Source: SEC companyfacts (US-GAAP 10-K). A * marks a computed figure, not a single XBRL tag. Fiscal years are as the issuer labels them. Follow The Filings does not adjust or audit these figures.

Ownership over time

13Fs that reported it each quarter. Click a bar for that quarter’s holders.